Navoximod (GDC-0919; Nlg-919) is an effective IDO (indoleamine-(2,3)-dioxygenase) inhibitor with Ki/EC50 of 7 nM/75 nM respectively.
Int Immunopharmacol. 2023 Dec;125(Pt B):111196.
Tryptophan metabolism regulates inflammatory macrophage polarization as a predictive factor for breast cancer immunotherapy
NLG-919 (Navoximod) purchased from AbMole
| Molecular Weight | 316.38 |
| Formula | C18H21FN2O2 |
| CAS Number | 1402837-78-8 |
| Solubility (25°C) | DMSO ≥ 40 mg/mL |
| Storage | -20°C, dry, sealed |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Related IDO Products |
|---|
| IDO-IN-18
IDO-IN-18 is an IDO inhibitor. |
| IDO1-IN-21
IDO1-IN-21 is an IDO1 inhibitor (IC50 = 0.64 μM). |
| IDO1-IN-22
IDO1-IN-22 is a IDO1 inhibitor (biochemical hIDO1 IC50: 67.4 nM, HeLa hIDO1 IC50: 17.6 nM). |
| IDO1/TDO-IN-6
IDO1/TDO-IN-6 is a dual inhibitor of IDO1/TDO with IC50s of 2.25 and 2.89 μM, respectively. |
| IDO-IN-13
IDO-IN-13 is a potent indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor with an EC50 of 17 nM, extracted from patent WO2019040102A1, example 43. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
